期刊
EUROPEAN RESPIRATORY JOURNAL
卷 44, 期 3, 页码 614-626出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00132213
关键词
-
资金
- European Community [211250]
- ECRHS
- EGEA
- E3N
- NSHD
- SALIA
- SAPALDIA
- European Commission
- Albacete: Fondo de Investigaciones Santarias [97/0035-01, 13 99/0034-01, 99/0034-02]
- Albacete: Hospital Universitario de Albacete
- Albacete: Consejeria de Sanidad
- Antwerp: FWO (Fund for Scientific Research) Flanders Belgium [G.0402.00]
- Antwerp: University of Antwerp
- Antwerp: Flemish Health Ministry
- Barcelona: Fondo de Investigaciones Sanitarias [99/0034-02, 99/0034-01]
- Barcelona: Red Respira [RTIC 03/11 ISC IIF]
- Erfurt: GSF National Research Centre for Environment and Health
- Erfurt: Deutsche Forschungsgemeinschaft (DFG) [FR 1526/1-1]
- Galdalcao: Basque Health Department
- Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]
- Grenoble: Ministry of Health, Direction de la Recherche Clinique
- Grenoble: Ministere de l'Emploi et de la Solidarite
- Grenoble: Direction Generale de la Sante
- Grenoble: CHU de Grenoble
- Grenoble: Comite des Maladies Respiratoires de l'Isere
- Ipswich: National Asthma Campaign (UK)
- Norwich: National Asthma Campaign (UK)
- Huelva: Fondo de Investigaciones Sanitarias (FIS) [97/0035-01, 99/0034-02, 99/0034-01]
- Oviedo: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-02, 99/0034-01]
- Paris: Ministere de l'Emploi et de la Solidarite
- Paris: Direction Generale de la Sante
- Paris: UCBPharma (France)
- Paris: Aventis (France)
- Paris: Glaxo France
- Paris: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]
- Paris: Ministry of Health
- Paris: Direction de la Recherche Clinique
- Paris: CHU de Grenoble
- Pavia: Glaxo, Smith Kline Italy
- Pavia: Italian Ministry of University and Scientific and Technological Research (MURST)
- Pavia: Local University Funding for Research, (Pavia, Italy)
- Turin: ASL 4 Regione Piemonte (Italy)
- Turin: AO CTO/ICORMA Regione Piemonte (Italy)
- Turin: Ministero dell'Universita e della Ricerca Scientifica (Italy)
- Turin: Glaxo Wellcome spa (Verona, Italy)
- Umea: Swedish Heart Lung Foundation
- Umea: Swedish Foundation for Health Care Sciences and Allergy Research
- Umea: Swedish Asthma and Allergy Foundation
- Umea: Swedish Cancer and Allergy Foundation
- Verona: University of Verona
- Verona: Italian Ministry of University and Scientific and Technological Research (MURST)
- Verona: Glaxo, Smith Kline Italy
- UK Medical Research Council [U1200632239, U12309272]
- German state (NRW)
- Federal Ministries of the Environment
- DGUV (German statutory accident assurance) [VT 266.1]
- Swiss National Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
- Federal Office for Forest, Environment and Landscape and several Federal and Cantonal authorities
- Swiss National Science Foundation
- German research Foundation D-A-CH grant [32473BM-133148]
- Medical Research Council [MC_UU_12019/1, G0901214, G0801056] Funding Source: researchfish
- Swiss National Science Foundation (SNF) [32473BM_133148] Funding Source: Swiss National Science Foundation (SNF)
- MRC [MC_UU_12019/1, G0901214, G0801056] Funding Source: UKRI
The role of air pollution in chronic obstructive pulmonary disease (COPD) remains uncertain. The aim was to assess the impact of chronic exposure to air pollution on COPD in four cohorts using the standardised ESCAPE exposure estimates. Annual average particulate matter (PM), nitrogen oxides (NOx) and road traffic exposure were assigned to home addresses using land-use regression models. COPD was defined by NHANES reference equation (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than the lower limit of normal) and the Global Initiative for Chronic Obstructive Lung Disease criterion (FEV1/FVC <0.70) and categorised by severity in non-asthmatics. We included 6550 subjects with assigned NOx and 3692 with PM measures. COPD was not associated with NO2 or PM10 in any individual cohort. In meta-analyses only NO2, NOx, PM10 and the traffic indicators were positively, although not significantly, associated with COPD. The only statistically significant associations were seen in females (COPD prevalence using GOLD: OR 1.57, 95% CI 1.11-2.23; and incidence: OR 1.79, 95% CI 1.21-2.68). None of the principal results were statistically significant, the weak positive associations of exposure with COPD and the significant subgroup findings need to be evaluated in further well standardised cohorts followed up for longer time, and with time-matched exposure assignments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据